Simplify Logo

Full-Time

Equity Administrator

Posted on 6/4/2024

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Compensation Overview

$95k - $120kAnnually

+ Discretionary Bonuses + Equity

Senior

New York, NY, USA

Category
Corporate Finance
Finance & Banking
Required Skills
Communications
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Minimum of 3-5 years of experience in stock plan administration.
  • BA/BS degree in related field.
  • Proficient with equity management platforms such as E*TRADE/Equity Edge Online and Carta preferred.
  • Strong understanding of equity compensation plans and relevant tax and securities regulations.
  • Excellent analytical, organizational, and communication skills.
  • Detail-oriented with a high level of confidentiality and integrity.
  • Highly innovative problem solver who demonstrates the ability to meet aggressive deadlines.
  • Proficient in Microsoft Excel and PowerPoint
Responsibilities
  • Administer all aspects of Roivant’s equity programs, including stock options, restricted stock units (RSUs), employe stock purchase plan (ESPP), and other equity awards.
  • Process equity grants, acceptances, exercises, cancellations, vesting and releases, and ESPP open enrollment according to plan requirements and company policies.
  • Maintain and update equity plan participant records, ensuring complete and accurate data.
  • Correctly reflect all equity transactions in the equity management system.
  • Support SOX compliance by adhering to all key controls.
  • Coordinate with payroll to ensure accurate tax withholding and reporting of equity transactions.
  • Work cross-functionally with other internal departments: Finance, Accounting, and Legal as well as external partners like our stock plan provider, broker, and transfer agent
  • Provide support and guidance to employees on all equity-related questions.
  • Ensure data integrity by completing regular reconciliations between HR, Payroll, and Equity records.
  • Assist with the preparation of proxy statements, annual reports, and other disclosures as needed.
  • Create ad hoc reports.
  • Special projects as needed, including equity system improvements and process automation.

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through licensing agreements, partnerships, and the sale of approved drugs, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

2%

1 year growth

2%

2 year growth

-21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE